Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are Revuforj, a menin inhibitor, which has completed phase 2 clinical trial for the treatment of relapsed or refractory and acute leukemia. The company is revumenib for R/R mNPM1 AML and studying the use of revumenib in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia across the treatment landscape, including in newly diagnosed patients. It also developing  Niktimvo, a colony stimulating factor-1 receptor, blocking antibody, which is in phase 2 clinical trial for the treatment of chronic graft-versus-host disease. The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

Syndax Pharmaceuticals Inc.

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on IN8bio (INAB), Syndax Pharmaceuticals (SNDX) and Ole...

Analysts Offer Insights on Healthcare Companies: IN8bio (INAB), Syndax Pharmaceuticals (SNDX) and Olema Pharmaceuticals (OLMA)

In a report released today, David Dai from UBS maintained a Buy rating on Syndax Pharmaceuticals, with a price target of $37.00. Dai covers the Hea...

Syndax Pharmaceuticals (SNDX) Gets a Buy from UBS

Stifel Nicolaus analyst Stephen Willey maintained a Buy rating on Syndax Pharmaceuticals today and set a price target of $46.00. Willey covers the ...

Stifel Nicolaus Sticks to Their Buy Rating for Syndax Pharmaceuticals (SNDX)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Centene (CNC) and Syndax Pharmaceuticals (SNDX). Centene (CNC) TD...

Market Cap	$1.27B	P/E Ratio	N/A
52W High	$25.59	52W Low	$8.59
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	-10.2%	52W Position	66.5%
Overall Score	40	Value Score	40
Quality Score	39	Technical Score	41

EPS Current Est	$-1.66	EPS Next Est	$-0.49
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	SNDX	$19.90	-0.20%	834.26K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	SNDX	$19.90	-0.2%	834.26K
3
4
5
6

SNDX

SNDX

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Syndax Pharmaceuticals Inc. Data in Excel

Get Syndax Pharmaceuticals Inc. Data in Excel